Reduction of the accumulation of advanced glycation end products by ACE inhibition in experimental diabetic nephropathy

Diabetes

Volumn 51, Issue 11, 2002, Pages 3274-3282

  Forbes, Josephine M ^a,c   Cooper, Mark E ^a   Thallas, Vicki ^a   Burns, Wendy C ^a   Thomas, Merlin C ^a   Brammar, Gail C ^a   Lee, Fiona ^a   Grant, Sharon L ^a   Burrell, Louise A ^a   Jerums, George ^b   Osicka, Tanya M ^b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b AUSTIN HEALTH   (Australia)

^c BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

3 NITROTYROSINE; ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; ADVANCED GLYCATION END PRODUCT RECEPTOR 2; ADVANCED GLYCATION END PRODUCT RECEPTOR 3; AMINOGUANIDINE; DIPEPTIDYL CARBOXYPEPTIDASE; GLYCOPROTEIN; GLYCOPROTEIN GP 91; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN ZINC SUSPENSION; RAMIPRIL; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; STREPTOZOCIN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; ENZYME INHIBITION; FLUORESCENCE; GENE EXPRESSION; GLYCATION; IMMUNOHISTOCHEMISTRY; MALE; MEMBRANE BINDING; NONHUMAN; OXIDATION; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; REDUCTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; STREPTOZOCIN DIABETES;

EID: 0036830463     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.51.11.3274     Document Type: Article

References (48)

1. Fu MX, Wells-Knecht KJ, Blackledge JA, Lyons TJ, Thorpe SR, Baynes JW: Glycation, glycoxidation, and cross-linking of collagen by glucose: Kinetics, mechanisms, and inhibition of late stages of the Maillard reaction. Diabetes 43:676-683, 1994
2. Brownlee M, Vlassara H, Kooney A, Ulrich P, Ceranu A: Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science 232:1629-1632, 1986
3. Soulis T, Cooper ME, Vranes D, Bucala R, Jerums G: The effects of aminoguanidine in preventing experimental diabetic nephropathy are related to duration of treatment. Kidney Int 50:627-634, 1996
4. Baynes JW: Role of oxidative stress in development of complications in diabetes. Diabetes 40:405-412, 1991
5. Nishikawa T, Edelstein D, Du XL, Yamagishi S, Matsumura T, Kaneda Y, Yorek MA, Beebe D, Oates PJ, Hammes HP, Giardino I, Brownlee M: Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 404:787-790, 2000
6. Yan SD, Schmidt AM, Anderson GM, Zhang J, Brett J, Zou YS, Pinsky D, Stern D: Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biol Chem 269:9889-9897, 1994
7. Scivittaro V, Ganz MB, Weiss MF: AGEs induce oxidative stress and activate protein kinase C-beta(II) in neonatal mesangial cells. Am J Physiol Renal Physiol 278:F676-F683, 2000
8. Wautier MP, Chappey O, Corda S, Stern DM, Schmidt AM, Wautier JL: Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am J Physiol Endocrinol Metab 280:E685-E694, 2001
9. Odetti P, Traverso N, Cosso L, Noberasco G, Pronzato MA, Marinari UM: Good glycaemic control reduces oxidation and glycation end-products in collagen of diabetic rats. Diabetologia 39:1440-1447, 1996
10. Suzuki D, Miyata T, Saotome N, Horie K, Inagi R, Yasuda Y, Uchida K, Izuhara Y, Yagame M, Sakai H, Kurokawa K: Immunohistochemical evidence for an increased oxidative stress and carbonyl modification of proteins in diabetic glomerular lesions. J Am Soc Nephrol 10:822-832, 1999
11. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy: the Collaborative Study Group. N Engl J Med 329:1456 -1462, 1993
12. Huang JS, Guh JY, Chen HC, Hung WC, Lai YH, Chuang LY: Role of receptor for advanced glycation end-product (RAGE) and the JAK/STAT-signaling pathway in AGE-induced collagen production in NRK-49F cells. J Cell Biochem 81:102-113, 2001
13. Sebekova K, Schinzel R, Munch G, Krivosikova Z, Dzurik R, Heidland A: Advanced glycation end-product levels in subtotally nephrectomized rats: Beneficial effects of angiotensin II receptor 1 antagonist losartan. Miner Electrolyte Metab 25:380-383, 1999
14. Rajagopalan S, Kurz S, Munzel T, Tarpey M, Freeman BA, Griendling KK, Harrison DG: Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation: Contribution to alterations of vasomotor tone. J Clin Invest 97:1916-1923, 1996
15. Bunag RD: Validation in awake rats of a tail-cuff method for measuring systolic pressure. J Appl Physiol 34:279-282, 1973
16. Soulisliparota T, Cooper ME, Dunlop M, Jerums G: The relative roles of advanced glycation, oxidation and aldose reductase inhibition in the development of experimental diabetic nephropathy in the Sprague-Dawley rat. Diabetologia 38:387-394, 1995
17. Cefalu WT, Wang ZQ, Bell-Farrow A, Kiger FD, Izlar C: Glycohemoglobin measured by automated affinity HPLC correlates with both short-term and long-term antecedent glycemia. Clin Chem 40:1317-1321, 1994
18. Hsu SM, Raine L, Fanger H: Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: A comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 29:577-580, 1981
19. Forbes JM, Soulis T, Thallas V, Panagiotopoulos S, Long DM, Vasan S, Wagle D, Jerums G, Cooper ME: Renoprotective effects of a novel inhibitor of advanced glycation. Diabetologia 44:108-114, 2001
20. Bian K, Davis K, Kuret J, Binder L, Murad F: Nitrotyrosine formation with endotoxin-induced kidney injury detected by immunohistochemistry. Am J Physiol 277:F33-F40, 1999
21. Youssef S, Nguyen DT, Soulis T, Panagiotopoulos S, Jerums G, Cooper ME: Effect of diabetes and aminoguanidine therapy on renal advanced glycation end-product binding. Kidney Int 55:907-916, 1999
22. Soulis-Liparota T, Cooper M, Papazoglou D, Clarke B, Jerums G: Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozocin-induced diabetic rat. Diabetes 40:1328-1334, 1991
23. Soulis T, Cooper ME, Sastra S, Thallas V, Panagiotopoulos S, Bjerrum OJ, Jerums G: Relative contributions of advanced glycation and nitric oxide synthase inhibition to aminoguanidine-mediated renoprotection in diabetic rats. Diabetologia 40:1141-1151, 1997
24. Wrobel K, Garay-Sevilla ME, Nava LE, Malacara JM: Novel analytical approach to monitoring advanced glycosylation end products in human serum with on-line spectrophotometric and spectrofluorometric detection in a flow system. Clin Chem 43:1563-1569, 1997
25. Bonnet F, Cooper ME, Kawachi H, Allen TJ, Boner G, Cao Z: Irbesartan normalises the deficiency in glomerular nephrin expression in a model of diabetes and hypertension. Diabetologia 44:874-877, 2001
26. Morrissey JJ, Klahr S: Rapid communication. Enalapril decreases nuclear factor kappa B activation in the kidney with ureteral obstruction. Kidney Int 52:926-933, 1997
27. Ruiz-Ortega M, Lorenzo O, Ruperez M, Egido J: ACE inhibitors and AT(l) receptor antagonists-beyond the haemodynamic effect. Nephrol Dial Transplant 15:561-565, 2000
28. Wolf G, Neilson EG: Angiotensin II as a renal growth factor. J Am Soc Nephrol 3:1531-1540, 1993
29. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345:861- 869, 2001
30. Heart Outcomes Prevention Evaluation Study Investigators: Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 355:253-259, 2000
31. Osicka TM, Kiriazis Z, Pratt LM, Jerums G, Comper WD: Ramipril and aminoguanidine restore renal lysosomal processing in streptozotocin diabetic rats. Diabetologia 44:230-236, 2001
32. Zatz R, Dunn BR, Meyer TW, Anderson S, Rennke HG, Brenner BM: Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest 77:1925-1930, 1986
33. Makita Z, Bucala R, Rayfield EJ, Friedman EA, Kaufman AM, Korbet SM, Barth RH, Winston JA, Fuh H, Manogue KR, et al: Reactive glycosylation endproducts in diabetic uraemia and treatment of renal failure. Lancet 343:1519-1522, 1994
34. Miyata T, Wada Y, Cai Z, Iida Y, Horie K, Yasuda Y, Maeda K, Kurokawa K, van Ypersele de Strihou C: Implication of an increased oxidative stress in the formation of advanced glycation end products in patients with end-stage renal failure. Kidney Int 51:1170-1181, 1997
35. Zou MH, Shi C, Cohen RA: High glucose via peroxynitrite causes tyrosine nitration and inactivation of prostacyclin synthase that is associated with thromboxane/prostaglandin H(2) receptor-mediated apoptosis and adhesion molecule expression in cultured human aortic endothelial cells. Diabetes 51:198-203, 2002
36. Beckman JS, Koppenol WH: Nitric oxide, superoxide, and peroxynitrite: The good, the bad, and ugly. Am J Physiol 271:C1424-C1437, 1996
37. Hodge J: Dehydrated foods: Chemistry of browning reactions in model systems. Agric Food Chem 1:928-943, 1953
38. Tilton RG, Chang K, Hasan KS, Smith SR, Petrash JM, Misko TP, Moore WM, Currie MG, Corbett JA, McDaniel ML, Williamson JR: Prevention of diabetic vascular dysfunction by guanidines: Inhibition of nitric oxide synthase versus advanced glycation end-product formation. Diabetes 42:221-232, 1993
39. Onozato ML, Tojo A, Goto A, Fujita T, Wilcox CS: Oxidative stress and nitric oxide synthase in rat diabetic nephropathy: Effects of ACEI and ARB. Kidney Int 61:186-194, 2002
40. Tsuchida K, Makita Z, Yamagishi S, Atsumi T, Miyoshi H, Obara S, Ishida M, Ishikawa S, Yasumura K, Koike T: Suppression of transforming growth factor beta and vascular endothelial growth factor in diabetic nephropathy in rats by a novel advanced glycation end product inhibitor, OPB-9195. Diabetologia 42:579-588, 1999
41. Wiemer G, Linz W, Hatrik S, Scholkens BA, Malinski T: Angiotensin-converting enzyme inhibition alters nitric oxide and superoxide release in normotensive and hypertensive rats. Hypertension 30:1183-1190, 1997
42. Wolff SP: Diabetes mellitus and free radicals: free radicals, transition metals and oxidative stress in the aetiology of diabetes mellitus and complications. Br Med Bull 49:642- 652, 1993
43. Fujii J, Myint T, Okado A, Kaneto H, Taniguchi N: Oxidative stress caused by glycation of Cu,Zn-superoxide dismutase and its effects on intracellular components. Nephrol Dial Transplant 11:34-40, 1996
44. Spitaler MM, Graier WF: Vascular targets of redox signaling in diabetes mellitus. Diabetologia 45:476-494, 2002
45. Pitkanen S, Robinson BH: Mitochondrial complex I deficiency leads to increased production of superoxide radicals and induction of superoxide dismutase. J Clin Invest 98:345-351, 1996
46. Li J, Qu X, Schmidt AM: Sp 1-binding elements in the promoter of RAGE are essential for amphoterin-mediated gene expression in cultured neuroblastoma cells. J Biol Chem 273:30870 -30878, 1998
47. Koya D, Jirousek MR, Lin YW, Ishii H, Kuboki K, King GL: Characterization of protein kinase C beta isoform activation on the gene expression of transforming growth factor-beta, extracellular matrix components, and prostanoids in the glomeruli of diabetic rats. J Clin Invest 100: 115-126, 1997
48. Osicka TM, Yu Y, Panagiotopoulos S, Clavant SP, Kiriazis Z, Pike RN, Pratt LM, Russo LM, Kemp BE, Comper WD, Jerums G: Prevention of albuminuria by aminoguanidine or ramipril in streptozotocin-induced diabetic rats is associated with the normalization of glomerular protein kinase C. Diabetes 49:87-93, 2000